DITAC is Duality’s proprietary topoisomerase inhibitor-based ADC platform, validated by the global clinical data from over 1,000 patients across the U.S., China, Europe, Australia and other major markets. This platform is developed by screening and optimizing a library of proprietary ADC components, including our proprietary payloads P1003 and P1021, through meaningful technological improvements. DITAC provides critical flexibility in designing ADCs with improved systemic stability, tumor-specific payload release, bystander-killing effects, and rapid payload clearance.

·  Duality Immune Toxin Antibody Conjugate

· 5 clinical assets

· 2 preclinical assets

· Topoisomerase-based ADC platform

· Higher therapeutic window

· Good tolerability profile demonstrated in >1,500 patients